Chicago, 5 June 2023: Adjuvant osimertinib can improve overall survival (OS) in patients with EGFR-mutated, early-stage non-small-cell lung cancer (NSCLC), according to results from the ADAURA trial presented at the ASCO Annual Meeting 2023.¹

View Details

Related News

• Zydus gets warning as FDA highlights glass contamination concerns and others (12-09-2024)

---

• MPIDC allotted land to 36 industries in Medical Devices Park, investment of 1.8k crore (12-09-2024)

---

• DCC asks states and UTs to ensure implementation of revised Schedule M (12-09-2024)

---

• NPPA fixes retail price of 62 new drugs, extends CP of knee implants (12-09-2024)

---

• US FDA Issues Revised Guidance On Controlling Nitrosamine Impurities In Pharmaceuticals (12-09-2024)

---

• Bharat Biotech collaborates with US-based Alopexx to develop antimicrobial vaccine (12-09-2024)

---

• DCGI suspends permission to Entod pharma's 'Presvu Eye Drops', company to challenge order in court (11-09-2024)

---

• Diagnostic kits for early detection of Alzheimer’s and cancer launched (11-09-2024)

---

• FDI equity inflow into pharma sector grows to $236 million in Q1FY25 (11-09-2024)

---

• Steroid Use Could Raise Diabetes Risk (11-09-2024)

---